Highly Sensitive Method Detects Malaria Parasites
|
By LabMedica International staff writers Posted on 18 Mar 2015 |

Image: A gametocyte of Plasmodium falciparum in a thin blood smear and also seen are ring-form trophozoites and a red blood cell exhibiting basophilic stippling (Photo courtesy of Dr. Mae Melvin).
A large proportion of asymptomatic malaria infections can only be identified by surveillance with molecular methods, yet these infections also contribute to onward transmission to mosquitoes.
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
Latest Microbiology News
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








